Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl Clarke

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Trials|June 9, 2014
Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trialCatherine M Sackley, Christina H Smith, Caroline Rick, et al.
Neurobiology of Aging|November 6, 2016
Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter studyLisa Wang, Michael G Heckman, Jan O Aasly, et al.
Neurology|July 13, 2012
Large-scale replication and heterogeneity in Parkinson disease genetic lociManu Sharma, John P A Ioannidis, Jan O Aasly, et al.
Neurology|September 11, 2015
Large-scale assessment of polyglutamine repeat expansions in Parkinson diseaseLisa Wang, Jan O Aasly, Grazia Annesi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 30, 2019
The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic InsightSara Bandres-Ciga, Sarah Ahmed, Marya S Sabir, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Trials|June 9, 2014
Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trialCatherine M Sackley, Christina H Smith, Caroline Rick, et al.
Neurobiology of Aging|November 6, 2016
Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter studyLisa Wang, Michael G Heckman, Jan O Aasly, et al.
Neurology|July 13, 2012
Large-scale replication and heterogeneity in Parkinson disease genetic lociManu Sharma, John P A Ioannidis, Jan O Aasly, et al.
Neurology|September 11, 2015
Large-scale assessment of polyglutamine repeat expansions in Parkinson diseaseLisa Wang, Jan O Aasly, Grazia Annesi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 30, 2019
The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic InsightSara Bandres-Ciga, Sarah Ahmed, Marya S Sabir, et al.
Pageof 2